Health and Fitness Health and Fitness
Tue, December 14, 2010
[ Tue, Dec 14th 2010 ] - Market Wire
Varian-Equipped Proton Therapy Center Becomes Fir .. y-Modulated Proton Therapy (IMPT) Cancer Treatmen
[ Tue, Dec 14th 2010 ] - Market Wire
Hythiam Announces New Board Member, Kelly McCrann
[ Tue, Dec 14th 2010 ] - Market Wire
Zynex Expands International Business Initiative
[ Tue, Dec 14th 2010 ] - Market Wire
Compugen Announces Positive Therapeutic Effect of .. GEN-15001 in Animal Model of Rheumatoid Arthritis
[ Tue, Dec 14th 2010 ] - Market Wire
MEDNAX Announces the Acquisition of San Antonio Pediatric Hospitalist Practice
[ Tue, Dec 14th 2010 ] - Market Wire
Human Genome Sciences Appoints Colin Goddard, Ph.D., to Its Board of Directors
[ Tue, Dec 14th 2010 ] - Market Wire
AngioDynamics to Report Fiscal 2011 Second Quarte .. sults and Hold Conference Call on January 4, 2011
Mon, December 13, 2010
[ Mon, Dec 13th 2010 ] - Market Wire
Inhibitex to Present at the 2010 Deutsche Bank BioFEST Conference on Tuesday, December 14th
[ Mon, Dec 13th 2010 ] - Market Wire
Richard Snchez, M.D., Named Chief Medical Officer of Molina Healthcare of Utah
[ Mon, Dec 13th 2010 ] - Market Wire
Registration Period for North American Companies for the 2011 IR Global Rankings Starts Tomorrow
[ Mon, Dec 13th 2010 ] - Market Wire
Schiff Nutrition International, Inc. Announces Timing of Fiscal 2011 Second Quarter Results
[ Mon, Dec 13th 2010 ] - Market Wire
Baxtera?s Board of Directors Approves New Share Repurchase Authorization of $2.5 Billion
[ Mon, Dec 13th 2010 ] - Market Wire
Inhibitex Reports Promising Top-Line Results from .. II Trial of FV-100 for the Treatment of Shingles
[ Mon, Dec 13th 2010 ] - Market Wire
Lannett Announces Proposed Public Offering of Common Stock
[ Mon, Dec 13th 2010 ] - Market Wire
WellCare Partners with The Results Companies to Bring More Than 200 Jobs to Central Florida
[ Mon, Dec 13th 2010 ] - Market Wire
CIGNA Announces Appearance at the 2011 J.P. Morgan Healthcare Conference
[ Mon, Dec 13th 2010 ] - Market Wire
SurModics Comments on Announcement by Ramius
[ Mon, Dec 13th 2010 ] - Market Wire
BrainStorm Announces Resignation of CEO and Appoi .. al of Israel in New York, Ambassador Alon Pinkas,
[ Mon, Dec 13th 2010 ] - Market Wire
Sanofi-Aventis, Republic Services, Citigroup, American International and General Motors
[ Mon, Dec 13th 2010 ] - Market Wire
Alliance HealthCare Services Schedules Conference .. bcast to Review Full Year 2011 Financial Guidance
[ Mon, Dec 13th 2010 ] - Market Wire
Seattle Genetics to Webcast Presentation at 2010 Deutsche Bank BioFEST
[ Mon, Dec 13th 2010 ] - Market Wire
Health Net Issues 2011 Earnings Guidance
[ Mon, Dec 13th 2010 ] - Market Wire
Response Genetics Announces New Data Supporting t .. sion to Help Personalize Cancer Therapy Selection
[ Mon, Dec 13th 2010 ] - Market Wire
CardioNet, Inc. Appoints Daniel Wisniewski Senior Vice President, Business Operations
[ Mon, Dec 13th 2010 ] - Market Wire
Swiss Cancer Center Begins Advanced Radiotherapy .. Using TrueBeam System from Varian Medical Systems
[ Mon, Dec 13th 2010 ] - Market Wire
Prince of Wales Hospital in Hong Kong First in As .. age-Guided RapidArc® Radiotherapy Using the UNIQ
[ Mon, Dec 13th 2010 ] - Market Wire
Health Canada Approves iTech Medicala?s Muscle Pattern Recognition (MPR) System
[ Mon, Dec 13th 2010 ] - Market Wire
International Stem Cell Corporation Announces $25 Million Common Stock Financing Agreement
[ Mon, Dec 13th 2010 ] - Market Wire
Unigene to Advance Phase 2 Development of Oral PT .. Amended and Restated Exclusive Worldwide License
[ Mon, Dec 13th 2010 ] - Market Wire
Biogen Idec y Swedish Orphan Biovitrum anuncian p .. te de su protena de fusin Factor VIII Fc recombin

Biogen Idec y Swedish Orphan Biovitrum anuncian primera administracin a paciente de su protena de fusin Factor VIII Fc recombin


Published on 2010-12-13 04:50:12 - Market Wire
  Print publication without navigation


WESTON, Massachussets & ESTOCOLMO--([ BUSINESS WIRE ])--[ Biogen Idec ] (NASDAQ: BIIB) y [ Swedish Orphan Biovitrum ] (STO: SOBI) han anunciado la satisfactoria administracin al primer paciente de la protena de fusin Factor VIII Fc recombinante de accin prolongada (rFVIIIFc) de las empresas durante un ensayo clnico de homologacin mundial. El estudio, denominado A-LONG, es un estudio de fase 2/3, multic�ntrico y abierto concebido para evaluar la seguridad, farmacocin�tica y eficacia de rFVIIIFc en pacientes con hemofilia A tratados previamente.

El comunicado en el idioma original, es la versin oficial y autorizada del mismo. La traduccin es solamente un medio de ayuda ydeber sercomparada con el texto en idioma original, que es la nica versin del texto que tendr validez legal.

Contributing Sources